化合物ML327 T4252

Product Introduction
Bioactivity


英文名: ML327

描述: ML327 是 MYC 的阻断剂，还可抑制 E-钙粘蛋白转录和逆转上皮间质转化。

细胞实验: ML327 is solubilized in DMSO for in vitro experiments.Cells are seeded onto 96-well plates at equivalent density (3,000 to 10,000 depending upon cell line), permitted to attach overnight, and treated with either ML327 (10 μM) or vehicle. Daily absorbance measurements (450 nm) using the cell counting kit are obtained. For estimation of IC50 values, cells are plated at equal density, permitted to attach, and baseline absorbance is obtained using cell counting kit. Cells are then treated with varying doses of ML327 (0.1 to 30 μM) and cell viability is measured 72 h after treatment.

动物实验: ML327 is solubilized in 70% polyethylene glycol for in vivo experiments.Male athymic nude mice (4 to 6 weeks old) are maintained as described. BE(2)-C cells xenografts are established as previously described. 1×106 cells/100 μL of HBSS is injected subcutaneously into flanks using a 26-gauge needle (n=10 per group). Mice are monitored daily for xenograft formation and assessed by measuring the two greatest perpendicular tumor diameter with venier calipers. Xenograft volumes are estimated using the following formula [(length×width2)/2]. Once tumors reach 75 to 100 mm3, mice are randomized to receive either 50 mg/kg of ML327 or control vehicle (70% polyethylene glycol) via intraperitoneal injection twice daily for 14d. Weight and tumor volume are recorded daily. After completion of two weeks of treatment, mice are euthanized and tumors are excised, weighed, and RNA is isolated.

体外活性: ML327 partially restores E-cadherin expression at the plasma membrane in NMuMG cells induced to undergo Epithelial-to-Mesenchymal Transition (EMT) by TGF-β1 treatment. Treatment with ML327 induces an elongated morphology in neuroblastoma cells. BE(2)-C cells treated with ML327 demonstrates G1 cell cycle arrest with a concordant decrease in S phase population, and a significant increase in the sub G0 population. ML327 induces the expression of CDH1 in all seven of the neuroblastoma cell lines with a 50 to 1,400-fold induction of CDH1 mRNA expression. ML327 blocks the expression of MYC family of oncogenic transcription factors in all tested neuroblastoma cell lines. Immunoblotting time course demonstrates early repression of N-MYC expression within 2 h of treatment with ML327 (10 μM). p53 levels are also suppressed by treatment with ML327.

体内活性: ML327 treatment results in a two-fold decrease in MYCN expression, confirming that ML327 inhibits xenograft MYCN expression (p=0.0035). ML327 treatment significantly reduces tumor volume by three-fold over the two-week treatment period (p=0.02). Tumor explant weights are approximately three-fold smaller in the ML327-treated mice (p=0.01). Mice treated with ML327 lost 12% more body weight compared to vehicle-treated mice.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 13.75 mg/mL (37.53 mM)


关键字: Autophagy | Myc | Inhibitor | ML-327 | inhibit | ML327 | ML 327 | c-Myc

相关产品: 10058-F4 | IRES-C11 | WBC100 | MYCMI-6 | Lusianthridin | MDEG-541 | NY2267 | 10074-A4 | Sanggenol L | Nicotinamide N-oxide

相关库: Anti-Cancer Metabolism Compound Library | Cell Cycle Compound Library | Glutamine Metabolism Compound Library | Anti-Cancer Compound Library | Inhibitor Library | Apoptosis Compound Library | Autophagy Compound Library | Reprogramming Compound Library | NO PAINS Compound Library | Bioactive Compound Library

化合物ML327 T4252信息由TargetMol中国为您提供，如您想了解更多关于化合物ML327 T4252报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途